Patient Symptoms Are Better Measure Of Decongestant’s Efficacy – FDA
This article was originally published in The Tan Sheet
The patient self-assessed nasal congestion symptom score, not nasal air resistance, is the preferred tool to evaluate the effectiveness of an oral nasal decongestant such as phenylephrine, according to a report by a division of FDA's Office of New Drugs
You may also be interested in...
Concerns about the safety and efficacy of nonprescription pediatric cough/cold products point to the need to re-examine the monograph system in the future, according to University of Florida pharmacy and pediatrics professor Leslie Hendeles, Pharm.D
A pharmacy professor intends to file a citizen petition asking FDA to re-examine the effectiveness of the nasal decongestant phenylephrine after the agency refused a similar request by Congress
Rep. Henry Waxman (D-Calif.) is calling for an FDA advisory panel to reconsider the efficacy of the nasal decongestant phenylephrine and re-evaluate its status as a monograph ingredient